To include your compound in the COVID-19 Resource Center, submit it here.

Genentech reports detailed data for Tecentriq in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower150 trial of Tecentriq atezolizumab as first-line treatment of advanced stage IV non-squamous non-small cell lung cancer, including results from a subgroup of patients with a T effector

Read the full 437 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE